艾米齐祖马布用于获得的血友病A:一个病例系列
Matthias M Engelen1,2, Johan Vandesande1, Johan De Bent1
1Hemophilia Center, University Hospitals Leuven, Leuven, Belgium.
概括
艾米奇祖马布在获得的血友病A (AHA) 患者中有效控制出血,没有观察到新的出血. 这种治疗,与标准治疗一起,导致改善了因子VIII活性和抑制剂回归,没有安全问题.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 艾米齐祖马布已被批准用于先天性血友病A,但缺乏获得性血友病A (AHA) 的随机试验.
- 获得的血友病A由于存在VIII因子抑制剂而带来了独特的挑战.
研究的目的:
- 评估获得血友病A型患者对埃米齐祖马布的临床和生化反应.
- 评估艾米齐祖马布在AHA中治疗出血事件的安全性和有效性.
主要方法:
- 对七名成年AHA患者的回顾性分析,这些患者接受了埃米齐祖马布治疗.
- 对凝血参数,出血事件和血栓事件的监测.
- 染色体FVIII测定用于评估类似艾米齐祖马布的活性和本地FVIII活性.
主要成果:
- 艾米齐祖马布,结合免疫抑制疗法,控制了所有出血发作,没有复发.
- 患者在12天内至少达到5%的FVIII类活性.
- 原生FVIII活性恢复到≥5%发生在128天,与抑制剂消失相吻合.
- 没有报告安全问题或血栓事件.
结论:
- 埃米齐祖马布是获得性血友病A的可行的治疗选择,在控制出血方面表现出有效性.
- 这项研究支持艾米齐祖马布在AHA患者中的使用,显示出积极的临床和生化结果.
- 进一步的研究可能会探索更大的队列来证实这些发现.
相关概念视频
02:45Blood Transfusion and Agglutination
10.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.9K
01:24Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K